Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 3/20 | 0.37 |
| ▸ | CNR2 | P34972 | 7/20 | 0.36 |
| ▸ | ATXN2 | Q99700 | 1/20 | 0.35 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.35 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2705546 | 0.82 | FFAR4 (0.39) | KMOMEN1KMT2AACACBCNR2 | |
| SCHEMBL2704510 | 0.82 | SLC6A4 (0.35) | ACACBCNR2CNR1FFAR4 | |
| SCHEMBL6550887 | 0.82 | ALOX5 (0.37) | MEN1KMT2A | |
| SCHEMBL31196325 | 0.80 | HPGD (0.40) | KMOMEN1KMT2AACACBCNR2 | |
| SCHEMBL26360891 | 0.79 | MEN1 (0.33) | MEN1KMT2A | |
| SCHEMBL16290804 | 0.78 | CDK2 (0.37) | ACACBCNR2PARP15PARP10PARP2 | |
| SCHEMBL12468508 | 0.77 | MCHR1 (0.35) | MEN1KMT2AACACBFFAR4 | |
| SCHEMBL31196319 | 0.77 | KMT2A (0.42) | MEN1KMT2A | |
| SCHEMBL6550881 | 0.75 | MEN1 (0.30) | MEN1KMT2A | |
| SCHEMBL14727025 | 0.74 | PDE4A (0.39) | KMOCNR2ATXN2FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11020381-B2 | Biaryloxy derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2021-06-01 | — | — | US | disclosed |
| US-20200230123-A1 | BIARYLOXY DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2020-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11020381-B2 | Biaryloxy derivatives as TTX-S blockers | SCN1B, SCN3A, SCN2B | KMO 1058/4885MEN1 3938/4885KMT2A 3239/4885 |
| US-20200230123-A1 | BIARYLOXY DERIVATIVES AS TTX-S BLOCKERS | SCN1B, SCN3A, SCN2B | KMO 1058/4885MEN1 3938/4885KMT2A 3239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.